SLV 317

Drug Profile

SLV 317

Alternative Names: SLV-317

Latest Information Update: 12 Jul 2007

Price : $50

At a glance

  • Originator Solvay
  • Class Indoles; Irritable bowel syndrome therapies; Morpholines; Piperazines
  • Mechanism of Action Neurokinin 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Irritable bowel syndrome

Most Recent Events

  • 12 Jul 2007 Discontinued - Phase-I for Irritable bowel syndrome in USA (PO)
  • 12 Jul 2007 Discontinued - Phase-I for Irritable bowel syndrome in Germany (PO)
  • 31 Aug 2006 A clinical study has been added to the adverse events section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top